 Connection
Wells Messersmith to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications Wells Messersmith has written about Vascular Endothelial Growth Factor A.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.700 |
|
|
|
-
Scott AJ, Basu Mallick A, Dotan E, Cohen SJ, Gold PJ, Hochster HS, Subramaniam S, Barzi A, Watts GS, Blatchford PJ, Messersmith WA. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). Cancer Res Commun. 2022 10; 2(10):1188-1196.
Score: 0.666
-
Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. 2012 Aug; 14(8):690-701.
Score: 0.021
-
Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther. 2006 Dec; 5(12):3240-7.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|